Oxidative stress (OS) is associated with many diseases ranging from cancer to neurodegenerative disorders. Nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) is one of the most effective cytoprotective controller against OS. Modulation of Nrf2 pathway constitutes a remarkable strategy in the antineoplastic treatments. A big number of Nrf2-antioxidant response element activators have been screened for use as chemo-preventive drugs in OS associated diseases like cancer even though activation of Nrf2 happens in a variety of cancers. Research proved that hyperactivation of the Nrf2 pathway produces a situation that helps the survival of normal as well as malignant cells, protecting them against OS, anticancer drugs, and radiotherapy. In this review, the modulation of the Nrf2 pathway, anticancer activity and challenges associated with the development of an Nrf2-based anti-cancer treatment approaches are discussed. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.

Pharmacological applications of Nrf2 inhibitors as potential antineoplastic drugs / Telkoparan-Akillilar, P; Suzen, S; Saso, L.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 20:8(2019). [10.3390/ijms20082025]

Pharmacological applications of Nrf2 inhibitors as potential antineoplastic drugs

Saso, L.
2019

Abstract

Oxidative stress (OS) is associated with many diseases ranging from cancer to neurodegenerative disorders. Nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) is one of the most effective cytoprotective controller against OS. Modulation of Nrf2 pathway constitutes a remarkable strategy in the antineoplastic treatments. A big number of Nrf2-antioxidant response element activators have been screened for use as chemo-preventive drugs in OS associated diseases like cancer even though activation of Nrf2 happens in a variety of cancers. Research proved that hyperactivation of the Nrf2 pathway produces a situation that helps the survival of normal as well as malignant cells, protecting them against OS, anticancer drugs, and radiotherapy. In this review, the modulation of the Nrf2 pathway, anticancer activity and challenges associated with the development of an Nrf2-based anti-cancer treatment approaches are discussed. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.
2019
antineoplastic agent; beta transducin repeat containing protein; bleomycin; BRCA2 protein; brusatol; camptothecin; dipeptidyl peptidase; DNA binding protein; doxorubicin; glutamate cysteine ligase; glycogen synthase kinase 3; glycogen synthase kinase 3beta; halofuginone; heme oxygenase 1; kelch like ECH associated protein 1; luteolin; oxaliplatin; peroxisome proliferator activated receptor alpha; protein inhibitor; quassinoid; retinoic acid receptor; retinoid X receptor alpha; RNA polymerase II; transcription factor Maf; transcription factor NF E2 p45 subunit; transcription factor Nrf2, antineoplastic activity; antioxidant responsive element; autoimmune disease; bladder cancer; breast cancer; cancer growth; carcinogenesis; cell protection; cell survival; chemoprophylaxis; colorectal cancer; defense mechanism; degenerative disease; detoxification; DNA methylation; down regulation; epigenetics; gene expression; human; lung cancer; melanoma; nonhuman; ovary cancer; oxidative stress; pancreas adenocarcinoma; regulatory T lymphocyte; Review; somatic mutation; ubiquitination; uterine cervix cancer; Antineoplastic drugs; Cancer; Cancer chemoprevention and therapy; Chemoresistance; Nrf2 inhibitors
01 Pubblicazione su rivista::01a Articolo in rivista
Pharmacological applications of Nrf2 inhibitors as potential antineoplastic drugs / Telkoparan-Akillilar, P; Suzen, S; Saso, L.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 20:8(2019). [10.3390/ijms20082025]
File allegati a questo prodotto
File Dimensione Formato  
Telkoparan-Akillilar_Pharmacological_2019.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 611.38 kB
Formato Adobe PDF
611.38 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1302391
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 38
social impact